NCT00638131终止3 期
Effect of Bosentan on Systemic and Renal Inflammatory Markers in Patients With Diabetic Nephropathy on Angiotensin II Receptor Blockers
Centre hospitalier de l'Université de Montréal (CHUM)1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF
研究概览
简要总结
There is little doubt of the necessity for further improvement in the prevention and therapy of end-stage renal disease. Despite the success of ARB in treating diabetic nephropathy, not all patients obtain satisfactory control of blood pressure, albuminuria and decline in renal function. Experimental data have provided us with a rationale for the potential added benefits of ET receptor blockade to the AII inhibition in diabetic renal protection. Considering the nephroprotective effect of bosentan in diabetic rats, clinical studies are warranted to assess whether ET receptor antagonism has additive renoprotective effects on top of AII inhibition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women ≥ 18 years of age with a body weight of ≥ 40 kg;
- •For female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using intrauterine devices (IUDs);
- •Patients diagnosed Type 2 diabetes with overt nephropathy (urinary albumin excretion ≥ 300mg/24h);
- •Patients on current treatment with angiotensin II receptor blockers for ≥ 3 months;
- •Patients stable for at least 3 months prior to screening (no change in medications for diabetic nephropathy);
- •Provide written informed consent;
排除标准
- •Patients with a history of pulmonary chronic obstructive disease, cardiac failure or coronary artery disease;
- •Patients with documented cancers, acute infections or chronic inflammatory diseases;
- •Patients who are pregnant or breast-feeding;
- •Patients with known hepatic disorders or AST and ∕or ALT upper than normal limit;
- •Patients with hemoglobin or hematocrit that is ≥ 30% below the normal range (patients with secondary polycythemia are permitted);
- •Patients with systolic blood pressure < 110mm Hg;
- •Patients with plasmatic albumin level < 30g/L;
- •Patients with a documented creatinine clearance ≤ 60ml/min;
- •Patients on anticoagulants or anti-inflammatory drugs, including cyclooxygenase inhibitors, AINS, prednisone and immunosuppressive drugs, platelet aggregation inhibitors, except low dose aspirin, ACE inhibitors, antidiabetic agents (rosiglitazone, pioglitazone) and antioxidants (vitamin E)(except statins or low-dose aspirin ≤ 80mg/day);
- •Patients on treatment or planned treatment with another investigational drug;
- •Patients who are receiving an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor, or with a prostanoid (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion;
- •Patients who are receiving calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) at inclusion or are expected to receive any of these drugs during the study;
- •Patients with a known hypersensitivity to bosentan or any of the excipients;
研究组 & 干预措施
1
Experimental
Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
干预措施: bosentan (Drug)
2
Placebo Comparator
placebo given bid same as experimental arm;
干预措施: bosentan (Drug)
结局指标
主要结局
change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF
时间窗: 16 weeks
次要结局
- change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;(16 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
The role of Bosentan in fontan patients: improvement of aerobic capacity.aerobic capacity (peak V’O2)quality of life prevalence of arrhythmiasprevalence of protein losing enteropathyNL-OMON24216none40
已完成
2 期
Bosentan Therapy in Children With Functional Single VentricleCongenital Heart DefectsFunctional Single VentricleNCT01662037Shanghai Jiao Tong University School of Medicine34
进行中（未招募）
不适用
The role of Bosentan in fontan patients: improvement of aerobic capacity - bosentan in fontan patientsTo study whether bosentan (endothelin receptor inhibitor) improves aerobic capacity (VO2max) and exercise performance in adult patients with a Fontan operation.MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-004533-21-NLICI50
已完成
不适用
Bosentan improves clinical Outcome of adults with congenital heart disease or mitral valve lesions who undergo CArdiac surgeryaangeboren hartafwijkingopen hart operatie risico1004697310007510NL-OMON36241Academisch Medisch Centrum110
已完成
2 期
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With SclerodermaScleroderma, SystemicPulmonary FibrosisNCT00070590Actelion132